Evotec Adjusts Revenue Guidance and Confirms Profit Guidance Anticipating a More Profitable Revenue Mix
Evotec SE (NASDAQ:EVO) has revised its fiscal year 2025 revenue guidance downward to €760-800 million from the previous €840-880 million, while maintaining its R&D and adjusted EBITDA guidance. The company's new strategy for sustainable growth is showing early results, with stronger-than-expected contributions from high-margin technology license deals.
Despite challenging market conditions affecting its Shared R&D base business in H1 2025, Evotec's cost optimization efforts through its Priority Reset program are exceeding initial targets. The company maintains its Outlook 2028, targeting revenue CAGR of 8-12% (2024-2028) and an adjusted EBITDA margin above 20% by 2028.
The strategic pivot towards a capex-lighter model and focus on high-margin technology licensing is expected to positively impact the company's margin profile.
Evotec SE (NASDAQ:EVO) ha rivisto al ribasso le previsioni di fatturato per l'anno fiscale 2025, portandole a €760-800 milioni rispetto ai precedenti €840-880 milioni, mantenendo però invariate le stime su R&S e EBITDA rettificato. La nuova strategia per una crescita sostenibile sta già dando risultati positivi, con contributi superiori alle aspettative derivanti da accordi di licenza tecnologica ad alto margine.
Nonostante le difficili condizioni di mercato che hanno influenzato il business Shared R&D nel primo semestre 2025, gli sforzi di ottimizzazione dei costi attraverso il programma Priority Reset stanno superando gli obiettivi iniziali. L'azienda conferma le previsioni per il 2028, puntando a un CAGR dei ricavi dell'8-12% (2024-2028) e a un margine EBITDA rettificato superiore al 20% entro il 2028.
La svolta strategica verso un modello con minori investimenti in capitale e l'attenzione alle licenze tecnologiche ad alto margine dovrebbe avere un impatto positivo sul profilo dei margini dell'azienda.
Evotec SE (NASDAQ:EVO) ha revisado a la baja su previsión de ingresos para el año fiscal 2025, ajustándola a €760-800 millones desde los anteriores €840-880 millones, manteniendo sin cambios sus proyecciones de I+D y EBITDA ajustado. La nueva estrategia para un crecimiento sostenible está mostrando resultados tempranos, con contribuciones superiores a lo esperado provenientes de acuerdos de licencias tecnológicas de alto margen.
A pesar de las condiciones de mercado desafiantes que afectaron su negocio base de I+D compartida en el primer semestre de 2025, los esfuerzos de optimización de costos mediante el programa Priority Reset están superando los objetivos iniciales. La compañía mantiene su perspectiva para 2028, con un objetivo de CAGR de ingresos del 8-12% (2024-2028) y un margen EBITDA ajustado superior al 20% para 2028.
El giro estratégico hacia un modelo con menor inversión en capital y el enfoque en licencias tecnológicas de alto margen se espera que impacten positivamente el perfil de márgenes de la empresa.
Evotec SE (NASDAQ:EVO)는 2025 회계연도 매출 전망을 기존 8억 4,000만~8억 8,000만 유로에서 7억 6,000만~8억 유로로 하향 조정했으나, 연구개발(R&D) 및 조정 EBITDA 전망은 유지했습니다. 지속 가능한 성장 전략이 초기 성과를 보이고 있으며, 고수익 기술 라이선스 계약에서 예상보다 강한 기여가 나타나고 있습니다.
2025년 상반기 공유 R&D 기반 사업에 어려운 시장 상황이 있었음에도 불구하고, Priority Reset 프로그램을 통한 비용 최적화 노력이 초기 목표를 초과 달성하고 있습니다. 회사는 2028년 전망을 유지하며, 2024~2028년 매출 연평균 성장률(CAGR) 8-12% 및 2028년까지 조정 EBITDA 마진 20% 이상을 목표로 하고 있습니다.
자본 지출을 줄인 모델로의 전략적 전환과 고수익 기술 라이선스에 집중하는 전략은 회사의 마진 구조에 긍정적인 영향을 미칠 것으로 기대됩니다.
Evotec SE (NASDAQ:EVO) a révisé à la baisse ses prévisions de chiffre d'affaires pour l'exercice 2025, les ajustant à 760-800 millions d'euros contre 840-880 millions d'euros auparavant, tout en maintenant ses prévisions de R&D et d'EBITDA ajusté. La nouvelle stratégie de croissance durable montre des résultats précoces, avec des contributions plus fortes que prévu provenant d'accords de licences technologiques à forte marge.
Malgré un contexte de marché difficile affectant son activité de R&D partagée au premier semestre 2025, les efforts d'optimisation des coûts via le programme Priority Reset dépassent les objectifs initiaux. L'entreprise maintient ses perspectives pour 2028, visant un taux de croissance annuel composé (CAGR) du chiffre d'affaires de 8 à 12 % (2024-2028) et une marge d'EBITDA ajusté supérieure à 20 % d'ici 2028.
Le virage stratégique vers un modèle moins intensif en capital et l'accent mis sur les licences technologiques à forte marge devraient avoir un impact positif sur le profil de marge de l'entreprise.
Evotec SE (NASDAQ:EVO) hat seine Umsatzprognose für das Geschäftsjahr 2025 von zuvor €840-880 Millionen auf €760-800 Millionen nach unten korrigiert, hält jedoch seine Prognosen für F&E und bereinigtes EBITDA aufrecht. Die neue Strategie für nachhaltiges Wachstum zeigt erste Ergebnisse, mit stärker als erwarteten Beiträgen aus margenstarken Technologie-Lizenzgeschäften.
Trotz herausfordernder Marktbedingungen, die das Shared R&D-Grundgeschäft im ersten Halbjahr 2025 beeinflussten, übertreffen die Kosteneinsparungen durch das Priority Reset-Programm die ursprünglichen Ziele. Das Unternehmen bestätigt seine Prognose für 2028 mit einem angestrebten Umsatz-CAGR von 8-12 % (2024-2028) und einer bereinigten EBITDA-Marge von über 20 % bis 2028.
Die strategische Ausrichtung auf ein kapitalärmeres Modell und der Fokus auf margenstarke Technologielizenzen sollen das Margenprofil des Unternehmens positiv beeinflussen.
- Cost savings from Priority Reset program exceeding initial targets
- Strong demand for high-margin technology license business
- Strategic shift to capex-lighter model improving margin profile
- Maintained adjusted EBITDA guidance of €30-50m despite lower revenue expectations
- Revenue guidance lowered to €760-800m from €840-880m
- H1 2025 group revenues below expectations
- Challenging market conditions affecting Shared R&D base business
Insights
Evotec's revenue guidance cut is offset by stronger high-margin license revenues and cost savings, maintaining profit outlook.
Evotec's guidance revision reveals a significant shift in business composition rather than deteriorating fundamentals. While lowering revenue expectations by approximately
The recalibration stems from two opposing forces: underperformance in their Shared R&D base business amid challenging market conditions, counterbalanced by stronger-than-anticipated high-margin technology license revenues. This evolution aligns with April's strategic pivot toward a capital-lighter model focused on scalable technology and service provision.
The company's cost optimization initiative ("Priority Reset") is exceeding targets, providing additional margin protection. This enhanced cost discipline, combined with the shift toward higher-margin revenue streams, explains how Evotec can maintain profit guidance despite reduced revenue expectations.
Most importantly, Evotec has reaffirmed its 2028 outlook, targeting
The unchanged R&D investment guidance (
Successful execution of new strategy for sustainable and profitable growth leading to changing revenue mix with strong demand for Evotec's differentiated platforms
High-margin technology license revenues expected to have a stronger impactthan anticipated
Significant cost optimization in excess of initial targets from Priority Reset
Shared R&D base businesscontinues to navigate in a challenging market environment
H1 2025 Group revenues below expectations; adj. EBITDA broadly in line with expectations
Revenue guidance adjusted; R&D and adjusted EBITDA guidance unchanged, reflecting improved revenue mix and cost discipline
Evotec confirms itsOutlook 2028
HAMBURG, DE / ACCESS Newswire / July 21, 2025 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ:EVO) today announced that it has updated its revenue guidance for the fiscal year 2025. R&D and adjusted EBITDA related guidance elements remain unaffected.
For the current fiscal year, the Company expects revenues in the range of
R&D expenditures are expected in a range of
Adjusted EBITDA 1 is expected to reach
Outlook 2028 remains unchanged with a targeted Group revenue CAGR 2024-2028 in a range of 8 -
1 Excluding potential costs related to the transformation program in 2025
CAGR: Compound annual growth rate
In April, Evotec announced its new strategy for sustainable and profitable growth. A key element of this strategy is the refocused growth path, building on existing and new partnerships and further strengthened by leveraging its capabilities as a scalable technology and service provider. This also includes pivoting to a capex lighter model.
The Company expects this value creation strategy to result in tangible results earlier than initially expected, driven by stronger than planned revenue contributions from high-margin technology license deals.
After generating revenues below expectations in H1 2025, the Shared R&D base business is expected to continue to operate in a challenging market in the second half of 2025.
Dr Christian Wojczewski, Chief Executive Officer of Evotec, said:
"Our strategy for sustainable and profitable growth is progressing as planned. Strong demand for higher margin businesses reflects the strength of our platforms and validates the decisions we've made around focus, partnerships, and capital efficiency. While some parts of our business continue to operate in a challenging market environment, the execution of our Priority Reset, and new strategy gives us confidence that we are well-positioned to deliver on our long-term ambitions."
The changing revenue mix is expected to positively influence the margin profile of the Evotec Group.
In parallel, Evotec accelerated the implementation of its Priority Reset focused on ensuring sustainable profitable growth and right-sizing the business. The cost savings generated through these transformation efforts are now expected to exceed targets announced during the Q1 2025 results call on 06 May 2025.
About Evotec SE
Evotec is a life science company that is pioneering the future of drug discovery and development. By integrating breakthrough science with AI-driven innovation and advanced technologies, we accelerate the journey from concept to cure - faster, smarter, and with greater precision.
Our expertise spans small molecules, biologics, cell therapies and associated modalities, supported by proprietary platforms such as Molecular Patient Databases, PanOmics and iPSC-based disease modeling.
With flexible partnering models tailored to our customers' needs, we work with all Top 20 Pharma companies, over 800 biotechs, academic institutions, and healthcare stakeholders. Our offerings range from standalone services to fully integrated R&D programs and long-term strategic partnerships, combining scientific excellence with operational agility.
Through Just - Evotec Biologics, we redefine biologics development and manufacturing to improve accessibility and affordability.
With a strong portfolio of over 100 proprietary R&D assets, most of them being co-owned, we focus on key therapeutic areas including oncology, cardiovascular and metabolic diseases, neurology, and immunology.
Evotec's global team of more than 4,800 experts operates from sites in Europe and the U.S., offering complementary technologies and services as synergistic centers of excellence. For additional information please go to www.evotec.com and follow us on X/Twitter @Evotec and LinkedIn.
Forward-looking statements
This announcement contains forward-looking statements concerning future events, including the proposed offering and listing of Evotec's securities. Words such as "anticipate," "believe," "could," "estimate," "expect," "intend," "may," "might," "plan," "potential," "should," "target," "would" and variations of such words and similar expressions are intended to identify forward-looking statements. Such statements include comments regarding Evotec's expectations for revenues, Group EBITDA and unpartnered R&D expenses. These forward-looking statements are based on the information available to, and the expectations and assumptions deemed reasonable by Evotec at the time these statements were made. No assurance can be given that such expectations will prove to have been correct. These statements involve known and unknown risks and are based upon a number of assumptions and estimates, which are inherently subject to significant uncertainties and contingencies, many of which are beyond the control of Evotec. Evotec expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Evotec's expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.
For further information, please contact:
Investor Relations
Volker Braun
EVP Head of Global Investor Relations & ESG
Volker.Braun@evotec.com
SOURCE: Evotec SE
View the original press release on ACCESS Newswire
FAQ
What is Evotec's (NASDAQ:EVO) revised revenue guidance for 2025?
How does Evotec's Priority Reset program affect its financial outlook?
What is Evotec's adjusted EBITDA guidance for 2025?
What are Evotec's long-term financial targets for 2028?
How is Evotec's new business strategy affecting its revenue mix?
